Literature DB >> 30825926

Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia.

U Vivian Ukah1, Beth Payne2, Hanna Karjalainen3, Eija Kortelainen3, Paul T Seed4, Frances Inez Conti-Ramsden4, Vivien Cao5, Hannele Laivuori6, Jennifer Hutcheon7, Lucy Chappell4, J Mark Ansermino2, Manu Vatish8, Christopher Redman8, Tang Lee9, Larry Li9, Laura A Magee4, Peter von Dadelszen4.   

Abstract

The fullPIERS model is a risk prediction model developed to predict adverse maternal outcomes within 48 h for women admitted with pre-eclampsia. External validation of the model is required before implementation for clinical use. We assessed the temporal and external validity of the fullPIERS model in high income settings using five cohorts collected between 2003 and 2016, from tertiary hospitals in Canada, the United States of America, Finland and the United Kingdom. The cohorts were grouped into three datasets for assessing the primary external, and temporal validity, and broader transportability of the model. The predicted risks of developing an adverse maternal outcome were calculated using the model equation and model performance was evaluated based on discrimination, calibration, and stratification. Our study included a total of 2429 women, with an adverse maternal outcome rate of 6.7%, 6.6%, and 7.0% in the primary external, temporal, and combined (broader) validation cohorts, respectively. The model had good discrimination in all datasets: 0.81 (95%CI 0.75-0.86), 0.82 (95%CI 0.76-0.87), and 0.75 (95%CI 0.71-0.80) for the primary external, temporal, and broader validation datasets, respectively. Calibration was best for the temporal cohort but poor in the broader validation dataset. The likelihood ratios estimated to rule in adverse maternal outcomes were high at a cut-off of ≥30% in all datasets. The fullPIERS model is temporally and externally valid and will be useful in the management of women with pre-eclampsia in high income settings although model recalibration is required to improve performance, specifically in the broader healthcare settings.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Maternal outcomes; Model validation; Pre-eclampsia; Prediction; Pregnancy hypertension; Prognosis

Mesh:

Year:  2018        PMID: 30825926     DOI: 10.1016/j.preghy.2018.01.004

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  4 in total

1.  Development and internal validation of a model to predict type 2 diabetic complications after gestational diabetes.

Authors:  Ugochinyere Vivian Ukah; Robert W Platt; Nathalie Auger; Kaberi Dasgupta; Natalie Dayan
Journal:  Sci Rep       Date:  2022-06-20       Impact factor: 4.996

Review 2.  A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics).

Authors:  Liona C Poon; Laura A Magee; Stefan Verlohren; Andrew Shennan; Peter von Dadelszen; Eyal Sheiner; Eran Hadar; Gerard Visser; Fabricio Da Silva Costa; Anil Kapur; Fionnuala McAuliffe; Amala Nazareth; Muna Tahlak; Anne B Kihara; Hema Divakar; H David McIntyre; Vincenzo Berghella; Huixia Yang; Roberto Romero; Kypros H Nicolaides; Nir Melamed; Moshe Hod
Journal:  Int J Gynaecol Obstet       Date:  2021-07       Impact factor: 4.447

3.  Placental growth factor for the prognosis of women with preeclampsia (fullPIERS model extension): context matters.

Authors:  U Vivian Ukah; Beth A Payne; Jennifer A Hutcheon; Lucy C Chappell; Paul T Seed; Frances Inez Conti-Ramsden; J Mark Ansermino; Laura A Magee; Peter von Dadelszen
Journal:  BMC Pregnancy Childbirth       Date:  2020-11-05       Impact factor: 3.007

4.  The impact of chronic kidney disease Stages 3-5 on pregnancy outcomes.

Authors:  Kate Wiles; Philip Webster; Paul T Seed; Katy Bennett-Richards; Kate Bramham; Nigel Brunskill; Sue Carr; Matt Hall; Rehan Khan; Catherine Nelson-Piercy; Louise M Webster; Lucy C Chappell; Liz Lightstone
Journal:  Nephrol Dial Transplant       Date:  2021-11-09       Impact factor: 5.992

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.